Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma

Biochemical and Biophysical Research Communications

Volumn 289, Issue 1, 2001, Pages 205-211

  Nagata, Kenji ^a   Hirono, Shuichi ^a   Ido, Akio ^a   Kataoka, Hiroaki ^a   Moriuchi, Akihiro ^a   Shimomura, Takeshi ^b   Hori, Takeshi ^a   Hayashi, Katsuhiro ^a   Koono, Masashi ^a   Kitamura, Naomi ^c   Tsubouchi, Hirohito ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Mitsubishi Tokyo Pharmaceuticals Inc   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Chronic hepatitis; HAI 1; Hepatocellular carcinoma; HGF; HGFA; Liver cirrhosis; Serine protease; Serine protease inhibitor

Indexed keywords

ALPHA FETOPROTEIN; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR TYPE 1; SCATTER FACTOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0035941035     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.5916     Document Type: Article

References (46)

1. Proteolytic activation of hepatocyte growth factor in response to tissue injury
2. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator
3. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator
4. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
5. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
6. Activation of the zymogen of hepatocyte growth factor activator by thrombin
7. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor, structural similarity of the protease precursor to blood coagulation factor XII
8. Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation
9. Hepatocyte growth factor activator inhibitor, a novel Kunitz- type serine protease inhibitor
10. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
11. Distribution of hepatocyte growth factor activator inhibitor type 1(HAI-1) in human tissues: Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues
12. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network
13. Hepatocyte growth factor enhances the invasion activity of human hepatocellular carcinoma cell lines
14. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase
15. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers
16. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice
17. Molecular and genetic analysis of liver oncogenesis in transforming growth factor α transgenic mice
18. Hepatocyte growth factor levels in liver and serum increase during chemical hepatocarcinogenesis
19. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells
20. Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cell
21. Induction of apoptosis by hepatocyte growth factor/scatter factor and its augmentation by phorbol esters in Meth A cells
22. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model
23. Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine
24. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines
25. The urokinase-type plasminogen activator system in cancer metastasis: A review
26. Serum hepatocyte growth factor levels in liver diseases: Clinical implications
27. Expression of the c-met protooncogene in human hepatoceltular carcinoma
28. c-met mRNA overexpression in human hepatocellular carcinoma
29. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c-met does
30. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma
31. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa
32. A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture
33. Tight control of gene expression in mammalian cells by tetracycline-responsive promotors
34. Activation of hepatocyte growth factor/scatter factor in human colorectal carcinomas
35. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma
36. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma
37. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats
38. Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease
39. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
40. Prognostic value of plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
41. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
42. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
43. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid β-protein precursor
44. Secretion of protease nexin-II/amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and protease inhibitors
45. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in pericellular microenvironment
46. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa